(go to content)

Castellano | Euskara | Français | English

 Imagen decorativa
DAR No 4: Linaclotide. Constella® in the symptomatic management of irritable bowel syndrome with constipation

Content tools

Share it

  • Meneame
  • Delicious
  • Twitter
  • Google
  • Facebook

The indication was granted...so what?


     
     Download pdf


  • Although authorized for irritable bowel syndrome with constipation it offers only symptomatic relief.
  • In the best of cases, one in five patients can benefit from treatment.
  • On the other hand, one in five patients can suffer from diarrhea as a secondary effect which can last for more than 28 days in half the cases.
  • There are no available studies evaluating linaclotide versus other recommended comparators (laxatives and spasmolytics).

 

Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)

 

 

 

 

Suggestions/Comments  

Government of Navarre

Contact us | Accessibility | Legal notice | Site map